Helen McIlleron MBChB, PhD, heads a pharmacokinetic research group in the Division of Clinical Pharmacology, University of Cape Town, South Africa. Her work evaluates antituberculosis and antiretroviral drug pharmacokinetics in patient populations.Drug-drug interactions in TB/HIV coinfected patients, optimizing dosing in neglected populations such as children and pregnant women and describing PK/PD relationships and interactions within antituberculosis regimens are key areas of interest. The group has a focus on the development of field-friendly pharmacokinetic sampling methods and analytical techniques suited to studying variability in patient populations. The group has established collaborations with Uppsala University and the University of Queensland to foster population modeling expertise and is part of the PKPDia consortium formed to optimize treatments for HIV, TB and malaria using population PK/PD modeling.